Alaunos Therapeutics (TCRT) Income towards Parent Company (2009 - 2026)

Alaunos Therapeutics has reported Income towards Parent Company for 18 years, with the latest figure at -$1.0 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company rose 7.33% year-over-year to -$1.0 million; the trailing twelve-month figure through Mar 2026 stood at -$4.1 million (changed 0.43% YoY), and the FY2025 full-year result was -$4.2 million, up 12.2% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$1.0 million, down from -$907000.0 in the prior quarter.
• The five-year high for Income towards Parent Company was -$755000.0 in Q4 2024, with the low at -$10.5 million in Q1 2023.
• Historically, Income towards Parent Company has averaged -$5.0 million across 5 years, with a median of -$1.7 million in 2024.
• Annual changes were most pronounced in 2024 — Income towards Parent Company soared 90.5% — and 2025, when it slipped 20.13%.
• Alaunos Therapeutics' Income towards Parent Company stood at -$9.4 million in 2022, then advanced by 15.52% to -$7.9 million in 2023, then soared by 90.5% to -$755000.0 in 2024, then fell by 20.13% to -$907000.0 in 2025, then fell by 11.58% to -$1.0 million in 2026.
• The last three Income towards Parent Company figures came in at -$1.0 million (Q1 2026), -$907000.0 (Q4 2025), and -$1.2 million (Q3 2025), per Business Quant data.